ADMA Biologics, Inc. (ADMA) - 10-K Summary
Business Context and Reporting Period
Company: ADMA Biologics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: ADMA is a U.S.-based biopharmaceutical company manufacturing specialty biologics for immunodeficient patients. Its primary products are ASCENIV and BIVIGAM (IVIG for Primary Immunodeficiency) and Nabi-HB (Hepatitis B Immune Globulin). The company operates two main segments: ADMA BioManufacturing (manufacturing and commercialization) and ADMA BioCenters (plasma collection).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $510.2 million | $426.5 million | +20% |
| Gross Profit | $292.8 million | $219.6 million | +33% |
| Gross Margin | 57.4% | 51.5% | +590 bps |
| Net Income (GAAP) | $146.9 million | $197.7 million | -26% |
| Adjusted EBITDA | $231.0 million | $164.6 million | +40% |
| Operating Cash Flow | $50.4 million | $118.7 million | -58% |
| Cash & Equivalents | $87.6 million | $103.1 million | -15% |
| Total Debt (Net) | $72.1 million | $72.3 million | Flat |
Note: Net Income decreased primarily due to a one-time $84.3 million deferred tax benefit recorded in 2024 related to the release of a valuation allowance, which did not recur in 2025.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 51% increase in ASCENIV sales ($362.5M in 2025 vs. $239.6M in 2024), offset by a 14% decline in BIVIGAM sales and a 75% decline in intermediates/other products.
- Margin Expansion: Gross margin improved to 57.4% due to a favorable product mix shift toward higher-margin IVIG products and reduced unabsorbed manufacturing expenses.
- Debt Refinancing: In August 2025, the company refinanced its Ares Credit Facility with a new $300 million senior secured credit facility from JPMorgan Chase (JPM), consisting of a $75 million term loan and a $225 million revolving facility. This resulted in a $3.3 million loss on extinguishment of debt.
- Strategic Divestiture: In December 2025, ADMA agreed to sell three plasma collection centers for $12.0 million. Two centers were sold by year-end; the third is expected to close in Q1 2026. This move aims to improve capital efficiency and secure long-term plasma supply agreements.
- Yield Enhancement: The FDA approved a new production process in April 2025 that increases yields by 20% or more from the same plasma volume. 2026 is expected to be the first full year of this enhanced production.
Guidance, Outlook, and Risks
- Outlook: Management projects 2026 revenues to exceed $635 million and 2027 revenues to exceed $775 million, driven by yield enhancements and ASCENIV growth. Adjusted Net Income is projected to exceed $255 million in 2026 and $315 million in 2027.
- Pipeline: The company is developing SG-001 (S. pneumoniae hyperimmune globulin), with a pre-IND package expected in 2026. A Commissioner's National Priority Voucher (CNPV) application was submitted in September 2025 to potentially accelerate FDA review.
- Label Expansion: A supplemental BLA for ASCENIV to include pediatric patients (age 2+) was filed in June 2025, with approval anticipated in H1 2026.
- Key Risks:
- Customer Concentration: Two customers (BioCare and CuraScript) accounted for 73% of 2025 revenues and 87% of accounts receivable.
- Supply Chain: Reliance on third-party vendors for fill-finish and high-titer plasma supply.
- Regulatory: Risks associated with FDA inspections, post-marketing commitments, and potential changes in reimbursement policies (Medicaid/Medicare).
- Volatility: Net income volatility due to tax law changes and one-time tax benefits.
Investor Verification Checklist
- Customer Concentration: Verify the stability of relationships with BioCare and CuraScript, which represent the vast majority of revenue and receivables.
- Yield Enhancement Realization: Monitor Q1-Q4 2026 results to confirm the realization of the projected 20%+ yield increase and associated margin expansion.
- Plasma Supply Agreements: Review the terms of the new long-term supply agreements with the purchasers of the divested plasma centers to ensure supply security through the late 2020s.
- ASCENIV Pediatric Approval: Track the FDA decision timeline for the pediatric label expansion filed in June 2025.
- Debt Covenants: Confirm ongoing compliance with the JPM Credit Agreement covenants (max leverage ratio 2.50x, min fixed charge coverage 1.20x).
- Tax Position: Assess the sustainability of the effective tax rate without the one-time 2024 valuation allowance release.